New-onset refractory status epilepticus(NORSE)is a rare and challenging condition characterized by refractory status epilepticus in an otherwise healthy patient without obvious causes.Increasing evidence suggests a ch...New-onset refractory status epilepticus(NORSE)is a rare and challenging condition characterized by refractory status epilepticus in an otherwise healthy patient without obvious causes.Increasing evidence suggests a change in cytokine profiles in NORSE.However,the clinical utility of cytokine testing remains uncertain,primarily because of the lack of robust study designs and limited sample sizes.A recent study published in Annals of Neurology investigated the cytokine profiles in both serum and cerebrospinal fluid samples of NORSE patients.The study found elevated levels of CXCL8,CCL2,and MIP-1αin the serum and elevated levels of IL-1ßin the cerebrospinal fluid of NORSE patients compared to those with other forms of refractory status epilepticus(RSE).Furthermore,patients with cryptogenic NORSE had even higher levels of CXCL8,CCL2,and MIP-1αin the serum.Patients with NORSE who exhibited elevated levels of innate immunity cytokines in the serum had worse outcomes at discharge and several months after the NORSE ended.In summary,these findings highlight the association between inflammation-related cytokines and NORSE,providing new insights into clinical diagnosis and treatment approaches.展开更多
INTRODUCTION Currently, the recommended therapy to control refractory status epilepticus （RSE） is intravenous （IV） anesthetics, such as midazolam, propofol, barbiturates, and so on. However, 15%-26% of RSE cases s...INTRODUCTION Currently, the recommended therapy to control refractory status epilepticus （RSE） is intravenous （IV） anesthetics, such as midazolam, propofol, barbiturates, and so on. However, 15%-26% of RSE cases still cannot be terminated.展开更多
基金National Natural Science Foundation of China(82201607).
文摘New-onset refractory status epilepticus(NORSE)is a rare and challenging condition characterized by refractory status epilepticus in an otherwise healthy patient without obvious causes.Increasing evidence suggests a change in cytokine profiles in NORSE.However,the clinical utility of cytokine testing remains uncertain,primarily because of the lack of robust study designs and limited sample sizes.A recent study published in Annals of Neurology investigated the cytokine profiles in both serum and cerebrospinal fluid samples of NORSE patients.The study found elevated levels of CXCL8,CCL2,and MIP-1αin the serum and elevated levels of IL-1ßin the cerebrospinal fluid of NORSE patients compared to those with other forms of refractory status epilepticus(RSE).Furthermore,patients with cryptogenic NORSE had even higher levels of CXCL8,CCL2,and MIP-1αin the serum.Patients with NORSE who exhibited elevated levels of innate immunity cytokines in the serum had worse outcomes at discharge and several months after the NORSE ended.In summary,these findings highlight the association between inflammation-related cytokines and NORSE,providing new insights into clinical diagnosis and treatment approaches.
基金This work is supported by grants from the National Natural Science Foundation of China （No. 81441037）, the National Key Department of Neurology funded by the Chinese Health and Family Planning Committee, and National Key Department of Critical-care medicine funded by the Chinese Health and Family Planning Committee.
文摘INTRODUCTION Currently, the recommended therapy to control refractory status epilepticus （RSE） is intravenous （IV） anesthetics, such as midazolam, propofol, barbiturates, and so on. However, 15%-26% of RSE cases still cannot be terminated.
